Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus

Command Hospital, India20 enrolled

Overview

To study the effects of GLP 1 analogues and DPP 4 inhibitors on newly detected type 1 diabetes patients.

Inclusion criteria T1DM \<3 months GAD Antibody+ Stimulated C peptide\<0.5ng/ml Ketosis at onset Age \< 30 yr Exclusion criteria Age \> 30 yr Pancreatic disease significant systemic complication

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Type 1 Diabetes

Interventions

InsulinDRUG

Exenatide Sitagliptin

SitagliptinDRUG

Sitagliptin 100 mg per day oral

ExenatideDRUG

Exenatide 10 micrograms daily twice

Eligibility

Sex: ALLMin age: 12 YearsMax age: 30 Years

Medical Language ↔ Plain English

Inclusion Criteria: * T1DM \<3 months * GAD Antibody+ or Stimulated C peptide\<0.5 ng/ml * Ketosis at onset * Age \< 30 yr Exclusion Criteria: * Age \> 30 yr * Pancreas disease * Significant systemic disease

Locations (1)

Command Hospital

Lucknow, Uttar Pradesh, India

Outcomes

Primary Outcomes

change in insulin requirement

To assess the change in insulin requirement with use of GLP 1 analogues or DPP 4 inhibitors along with insulin in type 1 diabetes

Time frame: one year

Secondary Outcomes

C peptide response

To assess the endogenous insulin secretion after one year of use of GLp 1 analogue and DPP 4 inhibitors

Time frame: at the end of one year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.